Dahlborg S A, Petrillo A, Crossen J R, Roman-Goldstein S, Doolittle N D, Fuller K H, Neuwelt E A
Department of Neurology, Oregon Health Sciences University, Portland 97201-3098, USA.
Cancer J Sci Am. 1998 Mar-Apr;4(2):110-24.
Radiographic tumor response and survival were evaluated in the pediatric and young adult population with germ cell tumor, primary CNS lymphoma, or primitive neuroectodermal tumor receiving intra-arterial carboplatin- or methotrexate-based chemotherapy with osmotic blood-brain barrier disruption (BBBD).
Thirty-four patients with histologically confirmed germ cell tumor (n = 9), primary CNS lymphoma (n = 9), or primitive neuroectodermal tumor (n = 16) were treated at the Oregon Health Sciences University from August 1981 through April 1995. Ages ranged from 1 to 30 years (mean, 18 years). Prior treatments included cranial radiation (n = 10) and chemotherapy (n = 18). All patients underwent extensive baseline neuropsychological evaluation and follow-up evaluation upon completion of the protocol, except for two patients who declined follow-up assessment.
Six hundred and forty-five BBBD procedures were performed with no mortality. Significant complications included one episode of tonsillar herniation with no neurologic sequelae, 4% incidence of seizures, and 3% incidence of sepsis or granulocytopenic fever. Ototoxicity was seen in 61% of patients who received carboplatin chemotherapy. Eighty-two percent of the patients had an objective response to treatment, including 62% with complete response and 20% with partial response. For most patients, cognitive functioning was maintained or improved at follow-up; this pattern was statistically significant. Three of the test scores for the seven patients who did not receive radiation therapy showed a cognitive decline of at least one standard deviation. Among the nine patients who received radiation therapy before or after BBBD chemotherapy, 11 test scores showed a decline in cognitive function at one standard deviation or more.
Durable responses were seen in patients with germ cell tumor and primary CNS lymphoma when treated with BBBD. Primitive neuroectodermal tumor requires post-chemotherapy radiotherapy for a durable response to be attained. Ototoxicity was a major form of toxicity in the patients who received carboplatin, but with the recent introduction of sodium thiosulfate, this problem has been markedly alleviated. Favorable cognitive outcomes appeared more likely for patients treated solely with BBBD chemotherapy and not with radiotherapy. Trends in the results for this sample are similar to those of previous research showing that radiotherapy is associated with cognitive decline. Current alternatives to enhanced drug delivery after BBBD include bone marrow transplantation; however, the increment in drug delivery is less, the number of courses is limited, and the morbidity and mortality are greater for bone marrow transplant than for BBBD. The current results suggest that in future trials, irradiation may not be needed in lymphoma and may not be necessary in some CNS germ cell tumors and that more focal radiotherapy should be further assessed in localized primitive neuroectodermal tumors.
评估接受动脉内基于卡铂或甲氨蝶呤的化疗并联合渗透性血脑屏障破坏(BBBD)的儿童和青年生殖细胞肿瘤、原发性中枢神经系统淋巴瘤或原始神经外胚层肿瘤患者的影像学肿瘤反应和生存率。
1981年8月至1995年4月期间,俄勒冈健康与科学大学对34例经组织学确诊的生殖细胞肿瘤(n = 9)、原发性中枢神经系统淋巴瘤(n = 9)或原始神经外胚层肿瘤(n = 16)患者进行了治疗。年龄范围为1至30岁(平均18岁)。既往治疗包括颅脑放疗(n = 10)和化疗(n = 18)。除两名拒绝随访评估的患者外,所有患者在方案完成后均接受了广泛的基线神经心理学评估和随访评估。
共进行了645次BBBD操作,无死亡病例。显著并发症包括1例扁桃体疝且无神经后遗症、癫痫发作发生率为4%、败血症或粒细胞缺乏性发热发生率为3%。接受卡铂化疗的患者中61%出现耳毒性。82%的患者对治疗有客观反应,包括62%完全缓解和20%部分缓解。对于大多数患者,随访时认知功能得以维持或改善;这种模式具有统计学意义。7例未接受放疗的患者中有3项测试分数显示认知下降至少1个标准差。在9例在BBBD化疗之前或之后接受放疗的患者中,11项测试分数显示认知功能下降1个标准差或更多。
接受BBBD治疗的生殖细胞肿瘤和原发性中枢神经系统淋巴瘤患者出现了持久反应。原始神经外胚层肿瘤需要化疗后放疗才能获得持久反应。耳毒性是接受卡铂治疗患者的主要毒性形式,但随着最近硫代硫酸钠的引入,这个问题已得到明显缓解。仅接受BBBD化疗而非放疗的患者似乎更有可能获得良好的认知结果。该样本结果趋势与先前研究相似,表明放疗与认知下降有关。BBBD后增强药物递送的当前替代方法包括骨髓移植;然而,骨髓移植的药物递送增量较小、疗程数量有限,且其发病率和死亡率高于BBBD。当前结果表明,在未来试验中,淋巴瘤可能无需放疗,一些中枢神经系统生殖细胞肿瘤可能也无需放疗,且应进一步评估局部原始神经外胚层肿瘤中更局部的放疗。